(Q47389809)

15 January 2018

title

Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy (English)

1 reference

15 January 2018

metastatic renal cell carcinoma

1 reference

1 reference

1 reference

Edith Huland

1

1 reference

15 January 2018

H Heinzer

2

1 reference

15 January 2018

R A Jörres

3

1 reference

15 January 2018

D Loppow

4

1 reference

15 January 2018

H Huland

5

1 reference

15 January 2018

publication date

1 September 2004

1 reference

15 January 2018

published in

Der Urologe. Ausg. A

1 reference

15 January 2018

volume

43 Suppl 3

1 reference

15 January 2018

page(s)

S140-4

1 reference

15 January 2018

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00120-004-0606-6

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00120-004-0606-6

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00120-004-0606-6

Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.

21 January 2018

1 reference

12 December 2020

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Spontaneous and interleukin-2-modulated cytokine release by bronchoalveolar cells in pulmonary malignancy

1 reference

12 December 2020

Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.

1 reference

12 December 2020

Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy

1 reference

12 December 2020

Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation.

1 reference

12 December 2020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2

1 reference

12 December 2020

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

12 December 2020

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome

1 reference

12 December 2020

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

12 December 2020

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha

1 reference

12 December 2020

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma

1 reference

12 December 2020

Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma

1 reference

12 December 2020

10.1007/S00120-004-0606-6

Identifiers

DOI

0 references

1 reference

15 January 2018